Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

DataMeds AI, Inc.

NASDAQ: MEDS · Trade & Services · 10 alerts · CIK 2030763

Share price
$0.6421Close, Nov 16
Market cap
$3.68M
Shares outstanding
5.72MLatest SEC cover page
Sector
Trade & Services
Industry
Wholesale-Drugs, Proprietaries & Druggists' SundriesSIC 5122

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All DataMeds AI, Inc. filings on SEC EDGAR ↗

6:14 AM ET 8-K
Capital Raise

DataMeds AI Capital Raise

DataMEDS AI, Inc. entered into an at-the-market (ATM) sales agreement with Dawson James Securities, Inc. to establish an offering program for its common stock. The company may sell shares from time to time at prevailing market prices, though it is not obligated to make any sales. The Sales Agent will receive a fixed commission of 3.0% of the gross proceeds from any shares sold.

Counterparty
Dawson James Securities, Inc.
5:01 PM ET 8-K
M&A Deal

DataMeds AI M&A Deal with EOS Technology Holdings, Inc.

DataMEDS AI entered into a second amended and restated non-binding letter of intent to acquire intellectual property assets from EOS and Scilex Holding Company, and a controlling interest in Tollo Health (d/b/a Health Lives Here). The transaction involves an exchange of membership interests and the issuance of common stock that will result in the counterparties owning approximately 89.5% of the company's common stock on a fully diluted basis.

Counterparty
EOS Technology Holdings, Inc.
9:24 AM ET 8-K
Nasdaq/NYSE Compliance Notice

DataMeds AI Nasdaq/NYSE Compliance Notice

DataMeds AI, Inc. received formal notification from Nasdaq on October 19, 2026, confirming that the company has regained compliance with the $2.5 million minimum stockholders' equity requirement for continued listing. The company had previously been in deficiency since April 2026 and had also recently regained compliance with the minimum bid-price requirement in June 2026.

Counterparty
Nasdaq
5:15 PM ET 8-K
Licensing Deal

DataMeds AI Licensing Deal with REBOOT Health AI, Inc. Worth $2M

DataMeds AI, Inc. entered into an exclusive intellectual property license agreement with REBOOT Health AI to use its AI platform for DataMeds' GLP-1 weight management business. As consideration, DataMeds will issue 666,667 shares of common stock with a guaranteed minimum value of $2 million after 180 days, plus a revenue-sharing arrangement. The company also disclosed it remains below Nasdaq's minimum stockholders' equity requirement for continued listing.

Value
$2M
Counterparty
REBOOT Health AI, Inc.
Term
perpetuity
5:12 PM ET 8-K
M&A Deal

DataMeds AI Signs $1.5M M&A Deal with Helomics Corporation

DataMeds AI acquired Helomics Corporation, an AI cancer diagnostics lab and precision oncology CRO, from Axe Compute Inc. for $1.5 million in total consideration consisting of 636,328 common shares and a $1.36 million convertible promissory note. The acquisition expands DataMeds' services into the oncology market and includes a CLIA/CAP-certified clinical laboratory and $1.5 million in cash.

Value
$1.5M
Counterparty
Helomics Corporation

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.